Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.
EXECUTIVE BIOGRAPHIES

Dr. Pauline Nys
Member

Areas of expertise include:
Physical and Chemical Kinetics and Thermodynamic; Absorption Processes of Organic compounds; Processes of Enzyme Engineering for Antibiotic production; Processes of Enzyme isolation, purification, modification and immobilization.

Research experience:
2003-up to date
Eastern Biotech Inc., New York, USA - Scientific Advisor

2000-2003
Piselli Consulting S.L., Barcelona Spain – Scientific Consultant

1962-2000
National Research Center for Antibiotics, Moscow, Russia - the major research center of pharmaceutical industry in the former Soviet Union.

Chief of the Lab. of Enzyme Engineering, Chief Research Scientist, Senior Research Scientist, Postgraduate Student responsible for:

-Elaboration the scientific basis for design and optimization of enzymatic processes and development of the original processes for production of antibacterial, anticancer, antifungal antibiotics and the key compounds required for their synthesis. The developed methods for beta lactam compounds were utilized by industry.

-Formulation the general principles of design the highly efficient biocatalyst for the synthesis and transformation of labile compounds on the base of immobilized enzymes and cells. Development of the novel industrial processes for biocatalyst production.

Education:
1990--National Research Center for Antibiotics, Moscow, Russia, Professor in Biotechnology

1984--National Research Center for Antibiotics, Moscow, Russia. Dr.of Sci. in Bioorganic Chemistry 1964-1968
Karpov Physico-Chemical Institute, Moscow, Russia. Ph. D. in Physical Chemistry. 1955-1960
University of Chemical Technology, Kazan, Russia. MS in Inorganic Chemistry.

Publications:
Over 250 scientific papers in Russian and International journals, significant part of which published in the US. Over 50 Author's Certificates (USSR patents), half of which have found practical application in industry.


Annex
1. "Comparison of the synthetic and hydrolytic activity of immobilized cephalexin-synthetase" – Biocatalysis, 1994, 11, 315-320.
2. "Role of biocatalysis in development and improvement of processes for production of betalactam antibiotics in Russia" - Antibiotiki i Khimioterapiya (Russia), 1994, 39, No 8, 3-14.
3. "Mathematical modelling and optimization of industrial processes for antibiotic production" – Preprints of the 6th Int. Conference on Computer Applications in Biotechnology, Garmisch-Partenkirchen, Germany, 1995, 268-271.
4. "Mathematical model of acyl transfer synthesis of semisynthetic cephalosporins"- IMACS/IFAC First Symp. on Mathematical modelling and simulation in agriculture and bio-industries, Brussel, Belgium, 1995,.1V, IV.B3-1 - IV.B3-5.
5. "Enzymatic synthesis of betalactam antibiotics. I. Cefazolin" - Antibiotiki i Khemioterapiya (Russia), 1999, No 5, 12-16
6. "Enzymatic synthesis of betalactam antibiotics. II. Aminocephalosporins"- Antibiotiki i Khemioterapiya (Russia), 1999, No 8, 6-11.
7. Analysis and prognosis of science in the area of antibiotic production in Russia". Pharmaceutical bulletin, 2000, ? 17, ?.18-19.
8. "Methodological approach to development of enzymatic technologies for semisynthetic antibiotic production"- Appl. Biochem. Biotechnol. 2000, Part A Enzyme Eng Biotechnol 88, 221-229.
9. "Enzymatic transformation of betalactam antibiotics. Trends of development and approaches to practical implementation." Moscow University Chemistry Bulletin, 2000, Special Issue, p.41-44
10. "Beta-lactam compounds. Interrelations of the structure and biological activity" Antibiotics and Chemotherapy, 2000, ? 11, 36-42
11. "Novel beta-lactam structures. The construction problems"- Antibiotics and Chemotherapy, 2002, ? 2, 29-37.
12. "Kinetic and thermodynamic approach to design the processes for enzymatic synthesis of betalactams" - Biocatalysis and Biotransformation, 2003, V. 20, N 1, pp.35-41.
13. "Combinatorial enzymology. Synthesis of novel betalactam libraries". Moscow University Chemistry Bulletin, 2003, Special Issue, p.137-141

Back to Science and Technology Advisory Committee

Partnering
Opportunities